Sweet GO FUSE!!
Well next week we will all know. With them in the quiet period till earnings anticipation is running high!! Will the be the report of the Smart Sponge leaving the train station!! Good luck to all longs.
agree perfect timing.
Nice green start for DROP today. They couldn't have planned it any better with TIger game back and probably the most watched event for golf.
Here is the scoop as I can't link
Zalicus Granted Key Formulation Patent for Z160
Extends Z160 Patent Coverage through March 2032
Business WirePress Release: Zalicus Inc. – 11 minutes agoEmail0Share0PrintRELATED QUOTESSymbol Price Change
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Zalicus Inc. (Nasdaq Global Market: ZLCS), a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today announced that it has been granted a patent by the U.S. Patent and Trademark office (USPTO) covering novel formulations of its product candidate Z160. United States patent number 8,409,560, entitled “Solid Dispersion Formulations and Methods of Use Thereof,” provides broad coverage for a range of novel Z160 pharmaceutical compositions and methods of using these compositions in the treatment of pain.
“We are delighted to have been issued this important patent extending Z160’s patent protection and exclusivity into 2032,” commented Mark H.N. Corrigan, MD, President and CEO of Zalicus. “Solid dispersion technology is well-characterized and has been utilized in a number of commercial and late-stage development products. Building on this knowledge, Zalicus has developed solid dispersion formulations of Z160 that have uniquely improved its bioavailability and have facilitated its advancement into two ongoing Phase 2a clinical trials in chronic neuropathic pain.”
Zalicus is currently advancing Z160, a first-in-class, oral, state-dependent, selective N-type calcium channel (Cav 2.2) blocker, through Phase 2a clinical development in chronic neuropathic pain. Z160 is designed to selectively target neuronal pain signaling by modulating neurons that are undergoing high-frequency firing. Z160 has demonstrated efficacy in multiple animal models of neuropathic and inflammatory pain, suggesting that it has the potential to treat a broad range of chronic pain conditions. Additionally, clinical trials in over 200 subjects have es